GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Divi's Laboratories Ltd (NSE:DIVISLAB) » Definitions » EV-to-Revenue
中文

Divi's Laboratories (NSE:DIVISLAB) EV-to-Revenue : 13.21 (As of Apr. 25, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Divi's Laboratories EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Divi's Laboratories's enterprise value is ₹976,334 Mil. Divi's Laboratories's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₹73,909 Mil. Therefore, Divi's Laboratories's EV-to-Revenue for today is 13.21.

The historical rank and industry rank for Divi's Laboratories's EV-to-Revenue or its related term are showing as below:

NSE:DIVISLAB' s EV-to-Revenue Range Over the Past 10 Years
Min: 8.05   Med: 12.68   Max: 37.03
Current: 13.21

During the past 13 years, the highest EV-to-Revenue of Divi's Laboratories was 37.03. The lowest was 8.05. And the median was 12.68.

NSE:DIVISLAB's EV-to-Revenue is ranked worse than
89.48% of 1027 companies
in the Drug Manufacturers industry
Industry Median: 2.3 vs NSE:DIVISLAB: 13.21

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-25), Divi's Laboratories's stock price is ₹3813.80. Divi's Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₹279.01. Therefore, Divi's Laboratories's PS Ratio for today is 13.67.


Divi's Laboratories EV-to-Revenue Historical Data

The historical data trend for Divi's Laboratories's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Divi's Laboratories EV-to-Revenue Chart

Divi's Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.14 9.79 13.72 12.97 9.24

Divi's Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.08 9.24 13.23 13.30 14.02

Competitive Comparison of Divi's Laboratories's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Divi's Laboratories's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Divi's Laboratories's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Divi's Laboratories's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Divi's Laboratories's EV-to-Revenue falls into.



Divi's Laboratories EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Divi's Laboratories's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=976334.070/73909.4
=13.21

Divi's Laboratories's current Enterprise Value is ₹976,334 Mil.
Divi's Laboratories's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹73,909 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Divi's Laboratories  (NSE:DIVISLAB) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Divi's Laboratories's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=3813.80/279.012
=13.67

Divi's Laboratories's share price for today is ₹3813.80.
Divi's Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹279.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Divi's Laboratories EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Divi's Laboratories's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Divi's Laboratories (NSE:DIVISLAB) Business Description

Traded in Other Exchanges
Address
Divi Towers, 1-72/23(P)/DIVIS/303, Babukhan Lane, Cyber Hills, Gachibowli, Hyderabad, TG, IND, 500032
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. Most of the company's sales are generated in Europe, followed by North America, India, and Asia. The company has three distinct business segments: Generic APIs, Custom Synthesis, and Nutraceuticals. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Divi's Laboratories (NSE:DIVISLAB) Headlines

No Headlines